M. Cavo, E. Terpos, C. Nanni, P. Moreau, S. Lentzsch et al., Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group, Lancet Oncol, vol.18, pp.206-223, 2017.

C. Bailly, R. Leforestier, B. Jamet, T. Carlier, M. Bourgeois et al., Imaging for initial staging and therapy assessment in multiple myeloma patients, Int J Mol Sci, vol.18, p.445, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01500327

T. B. Bartel, J. Haessler, T. Brown, J. D. Shaughnessy, F. Van-rhee et al., F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, vol.114, pp.2068-76, 2009.

E. Zamagni, F. Patriarca, C. Nanni, B. Zannetti, E. Englaro et al., Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation, Blood, vol.118, pp.5989-95, 2011.

J. E. Mcdonald, M. M. Kessler, M. W. Gardner, A. F. Buros, J. A. Ntambi et al., Assessment of total lesion glycolysis by 18F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma, Clin Cancer Res, vol.23, pp.1981-1988, 2017.

P. Moreau, M. Attal, D. Caillot, M. Macro, L. Karlin et al., Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM Study, J Clin Oncol, 2017.

S. Kumar, B. Paiva, K. C. Anderson, B. Durie, O. Landgren et al., International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, vol.17, pp.328-346, 2016.

C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani et al., Early 18F-FDG PET for prediction of prognosis in patients with diffuse large b-cell lymphoma: SUV-based assessment versus visual analysis, J Nucl Med, vol.48, pp.1626-1658, 2007.

C. Nanni, A. S. Cottereau, E. Lopci, C. Bodet-milin, M. Coronado et al., Report of the 6th International workshop on PET in lymphoma, Leuk Lymphoma, vol.58, pp.2298-303, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01742975

M. Attal, V. Lauwers-cances, C. Hulin, X. Leleu, D. Caillot et al., Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma, N Engl J Med, vol.376, pp.1311-1331, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01557406

E. Itti, C. Lin, J. Dupuis, G. Paone, D. Capacchione et al., Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy, J Nucl Med, vol.50, pp.527-560, 2009.

M. Meignan, A. Gallamini, M. Meignan, A. Gallamini, and C. Haioun, Report on the first international workshop on interim-PET-scan in lymphoma, Leuk Lymphoma, vol.50, pp.1257-60, 2009.

C. Nanni, A. Versari, S. Chauvie, E. Bertone, A. Bianchi et al., Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe), Eur J Nucl Med Mol Imaging, vol.45, pp.712-721, 2018.

F. H. Fahey, P. E. Kinahan, R. K. Doot, M. Kocak, H. Thurston et al., Variability in PET quantitation within a multicenter consortium, Med Phys, vol.37, pp.3660-3666, 2010.

S. Annunziata, A. Cuccaro, M. L. Calcagni, S. Hohaus, A. Giordano et al., Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET), Ann Nucl Med, vol.30, pp.588-92, 2016.

B. Durie, J. Harousseau, J. S. Miguel, J. Blad-e, B. Barlogie et al., International uniform response criteria for multiple myeloma, Leukemia, vol.20, pp.1467-73, 2006.

B. Lausen, R. Lerche, and M. Schumacher, Maximally selected rank statistics for dose-response problems, Biom J, vol.44, pp.131-178, 2002.

S. Z. Usmani, A. Mitchell, S. Waheed, J. Crowley, A. Hoering et al., Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3, Blood, vol.121, pp.1819-1842, 2013.

E. Itti, M. Meignan, A. Berriolo-riedinger, A. Biggi, and A. F. Cashen, An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DSUVmax, Eur J Nucl Med Mol Imaging, vol.40, pp.1312-1332, 2013.

M. Meignan, A. Gallamini, E. Itti, S. Barrington, C. Haioun et al., Report on the third international workshop on interim positron emission tomography in lymphoma, Leuk Lymphoma, pp.1-6, 2011.

M. Meignan, E. Itti, A. Gallamini, and A. Younes, FDG PET/CT imaging as a biomarker in lymphoma, Eur J Nucl Med Mol Imaging, vol.42, pp.623-656, 2015.

S. F. Barrington and R. Kluge, FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas, Eur J Nucl Med Mol Imaging, vol.44, pp.97-110, 2017.
DOI : 10.1007/s00259-017-3690-8
URL : https://doi.org/10.1007/s00259-017-3690-8

D. Dytfeld, K. A. Griffith, J. Friedman, D. Lebovic, C. Harvey et al., Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain-and M-protein-based model: extended follow-up of a phase II trial, Leuk Lymphoma, vol.52, pp.1271-80, 2011.

R. Casasnovas, M. Meignan, A. Berriolo-riedinger, S. Bardet, A. Julian et al., SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma, Blood, vol.118, pp.37-43, 2011.